



5 February 2019

Motif Bio plc
("Motif Bio" or the "Company")

Exercise of Warrants

Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced that it has received notification from warrant holders to exercise warrants representing 113,396 ordinary shares of 1p each ("Ordinary Shares") in the Company for total consideration of £36,513.52. The exercise price of all warrants was 32.2p per warrant.

Application has been made for the 113,396 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on 8 February 2019. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Following Admission, and further to the announcement made on 23 January 2019, and for the purposes of the Disclosure Guidance and Transparency Rules, the Company's total issued share capital will consist of 297,491,023 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.

For further information please contact:

Motif Bio plc info@motifbio.com
Graham Lumsden (Chief Executive Officer)

Peel Hunt LLP (NOMAD & BROKER) + 44 (0)20 7418 8900
Dr Christopher Golden
Oliver Jackson

Walbrook PR Ltd. (UK FINANCIAL PR & IR) +44 (0)20 7933 8780
Paul McManus/Helen Cresswell/Lianne Cawthorne motifbio@walbrookpr.com

MC Services AG (EUROPEAN IR) +49 (0) 89 210 2280
Raimund Gabriel raimund.gabriel@mc-services.eu

Solebury Trout (U.S. IR) + 1 (646) 378-2963
Meggie Purcell mpurcell@troutgroup.com

Russo Partners (U.S. PR) +1 (858) 717-2310 or +1 (212) 845 4272
David Schull david.schull@russopartnersllc.com
Travis Kruse, Ph.D. travis.kruse@russopartnersllc.com